acute oral toxicity (E) summary rat LD50 = 16 000 mg/kg (sorbitan (Rodford, 1996) Test acute dermal toxicity (A) full study rat Outcome LD50 > 2 000 mg/kg Chemical type/Reference (Priolube 3987) (Debets, 1984) dermal toxicity (B) full study rat LD50 > 2 000 mg/kg (RB 105) acute inhalation toxicity (A) summary rat/guinea pig 28.1 L/L 1.97 L/L (caprylic/capric triglyceride) (Rodford, 1996) inhalation toxicity (B) summary rat 2 mg/L (TMP) (Rodford, 1996) skin irritation (A) full study rabbit slight to moderate (RB 105) skin irritation (B) full study rabbit non-irritant (Priolube 3987) (Weterings, 1984) skin irritation (C) summary rabbit slight irritant (TMP (Rodford, 1996) skin irritation (D) summary rabbit skin tricaprylate/tricaprate
rabbit slight irritant (pentaerythritol tetraisostearate) (Rodford, 1996) Test Species Outcome Chemical type\Reference human non-irritant (pentaerythritol tetraisostearate) (Rodford, 1996) eye irritation (A) full rabbit non-irritant (RB 105) eye irritation (C) summary rabbit slight irritant glycol lene glycol diisostearate/pentaeryt hritol tetraisostearate) (Rodford, 1996) rabbit non-irritant (sorbitan monoisostearate) (Rodford, 1996) skin sensitisation (A) full study guinea pig non-sensitiser (RB 105) skin sensitisation (B) summary guinea pig non-sensitiser (caprylic/capric triglyceride) (Rodford, 1996) skin sensitisation (C) summary human triglyceride) (Rodford, 1996)
at 0.13 and 1.1 mg/L changes observed in circulatory system, inflammatory and degenerative organs (TMP) (Rodford, 1996) chronic oral toxicity rat at 20% for up to 18 months no toxic effects (caprylic/capric triglyceride oils) (Rodford, 1996) carcinogenicity rat mouse no tumourigenic response no tumourigenic response (caprylic/capric triglyceride oils) (caprylic/capric triglyceride oils) (Rodford, 1996) NMU rat (mammary tumour model) significantly lower total mammary tumours (caprylic/capric triglyceride oils) (Rodford, 1996) Subacute Oral Toxicity (RB 105) Species/strain: Number/sex of animals: 20/sex Method of administration: gavage;vehicle arachis oil BP Dose/Study duration: test substance administered daily for a total of 28 days: control 0 mg/kg/day low dose 150 mg/kg/day mid dose 400 mg/kg/day high dose 1 000 mg/kg/day Test method: OECD TG 407 Clinical observations: no clinical signs noted in any dose group Clinical chemistry/ Haematology no treatment related effects were detected Urinalysis: no treatment related effects Histopathology: no treatment related changes Organ Weights: no treatment related effects
MATERIAL SAFETY DATA SHEET The MSDS for the notified chemical was provided in a format consistent with the National Code of Practice for the Preparation of Material Safety Data Sheets (National Occupational Health and Safety Commission, 1994b). This MSDS was provided by the applicant as part of the notification statement. It is reproduced here as a matter of public record. The accuracy of this information remains the responsibility of the applicant. REQUIREMENTS FOR SECONDARY NOTIFICATION Under the Act, secondary notification of the notified chemical shall be required if any of the circumstances stipulated under subsection 64(2) of the Act arise. No other specific conditions are prescribed.